ED-71 clinical Study Using Alfacalcidol as the Comparator on Bone Mineral Density in Patients With Primary Osteoporosis
Latest Information Update: 07 Dec 2021
At a glance
- Drugs Eldecalcitol (Primary) ; Alfacalcidol
- Indications Osteoporosis
- Focus Registrational; Therapeutic Use
- Sponsors Chugai Pharmaceutical
- 21 Mar 2018 According to a Chugai Pharmaceutical media release, based on the data from this trial, the China Food and Drug Administration (CFDA) has accepted for review a New Drug Application (NDA) submitted for eldecalcitol (Edirol)
- 08 Feb 2018 Status changed from active, no longer recruiting to completed.
- 06 Nov 2017 According to a Chugai Pharmaceutical media release, regulatory filing for eldecalcitol is planned for 2018 after the results of this trial have been collated in China.